Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Identifieur interne : 003B26 ( Main/Exploration ); précédent : 003B25; suivant : 003B27Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Auteurs : Maxime Dougados [France] ; Karsten Kissel [Australie] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martin Mola [Espagne] ; Georg Schett [Allemagne] ; Roberto Gerli [Italie] ; Michael Sejer Hansen [Danemark] ; Howard Amital [Israël] ; Ricardo M. Xavier [Brésil] ; Orrin Troum [États-Unis] ; Corrado Bernasconi [Suisse] ; T W J. Huizinga [Pays-Bas]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2014.
Abstract
To assess the 1-year efficacy and safety of a regimen of tocilizumab plus methotrexate or placebo, which was augmented by a treat-to-target strategy from week 24.
ACT-RAY was a double-blind, 3-year trial. Adults with active rheumatoid arthritis despite methotrexate were randomised to add tocilizumab to ongoing methotrexate (add-on strategy) or to switch to tocilizumab plus placebo (switch strategy). Tocilizumab 8 mg/kg was administered every 4 weeks. Conventional open-label disease-modifying antirheumatic drugs (DMARDs) other than methotrexate were added at week 24 or later in patients with DAS28>3.2.
556 patients were randomised; 85% completed 52 weeks. The proportion of patients receiving open-label DMARDs was comparable in the add-on (29%) and switch (33%) arms. Overall, week 24 results were maintained or further improved at week 52 in both arms. Some endpoints favoured the add-on strategy. Mean changes in Genant-modified Sharp scores were small; more add-on (92.8%) than switch patients (86.1%) had no radiographic progression. At week 52, comparable numbers of patients had antidrug antibodies (ADAs; 1.5% and 2.2% of add-on and switch patients, respectively) and neutralising ADAs (0.7% and 1.8%). Rates of serious adverse events and serious infections per 100 patient-year (PY) were 11.3 and 4.5 in add-on and 16.8 and 5.5 in switch patients. In patients with normal baseline values, alanine aminotransferase elevations >3× upper limit of normal were observed in 11% of add-on and 3% of switch patients.
Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add-on and switch strategies led to meaningful clinical and radiographic responses.
Url:
DOI: 10.1136/annrheumdis-2013-204761
PubMed: 24473673
PubMed Central: 3995223
Affiliations:
- Allemagne, Australie, Brésil, Danemark, Espagne, France, Israël, Italie, Pays-Bas, Royaume-Uni, Suisse, États-Unis
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 002256
- to stream Pmc, to step Curation: 002106
- to stream Pmc, to step Checkpoint: 001704
- to stream Ncbi, to step Merge: 001751
- to stream Ncbi, to step Curation: 001751
- to stream Ncbi, to step Checkpoint: 001751
- to stream Main, to step Merge: 003B73
- to stream Main, to step Curation: 003B26
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study</title><author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name><affiliation wicri:level="1"><nlm:aff id="af1"><addr-line>Rheumatology B Department</addr-line>,<institution>Paris-Descartes University, Cochin Hospital</institution>,<addr-line>Paris</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kissel, Karsten" sort="Kissel, Karsten" uniqKey="Kissel K" first="Karsten" last="Kissel">Karsten Kissel</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Roche Products Pty Ltd</institution>,<addr-line>Dee Why</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Conaghan, Philip G" sort="Conaghan, Philip G" uniqKey="Conaghan P" first="Philip G" last="Conaghan">Philip G. Conaghan</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit</institution>,<addr-line>Leeds</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mola, Emilio Martin" sort="Mola, Emilio Martin" uniqKey="Mola E" first="Emilio Martin" last="Mola">Emilio Martin Mola</name><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>Department of Rheumatology</addr-line>,<institution>Hospital Universitario La Paz</institution>,<addr-line>Madrid</addr-line>,<country>Spain</country></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Schett, Georg" sort="Schett, Georg" uniqKey="Schett G" first="Georg" last="Schett">Georg Schett</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Department of Internal Medicine and Institute for Clinical Immunology</addr-line>,<institution>University of Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Gerli, Roberto" sort="Gerli, Roberto" uniqKey="Gerli R" first="Roberto" last="Gerli">Roberto Gerli</name><affiliation wicri:level="1"><nlm:aff id="af6"><addr-line>Rheumatology Unit, Department of Medicine</addr-line>,<institution>University of Perugia</institution>,<addr-line>Perugia</addr-line>,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Hansen, Michael Sejer" sort="Hansen, Michael Sejer" uniqKey="Hansen M" first="Michael Sejer" last="Hansen">Michael Sejer Hansen</name><affiliation wicri:level="1"><nlm:aff id="af7"><addr-line>Department of Internal Medicine and Rheumatology</addr-line>,<institution>Copenhagen University Hospital</institution>,<addr-line>Gentofte</addr-line>,<country>Denmark</country></nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Amital, Howard" sort="Amital, Howard" uniqKey="Amital H" first="Howard" last="Amital">Howard Amital</name><affiliation wicri:level="1"><nlm:aff id="af8"><addr-line>Department of Internal Medicine B and Research Center for Autoimmune Diseases</addr-line>,<institution>Sheba Medical Center</institution>,<addr-line>Tel-Hashomer</addr-line>,<country>Israel</country></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Xavier, Ricardo M" sort="Xavier, Ricardo M" uniqKey="Xavier R" first="Ricardo M" last="Xavier">Ricardo M. Xavier</name><affiliation wicri:level="1"><nlm:aff id="af9"><addr-line>Division of Rheumatology</addr-line>,<institution>Hospital de Clínicas de Porto Alegre</institution>,<addr-line>Porto Alegre</addr-line>,<country>Brazil</country></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Troum, Orrin" sort="Troum, Orrin" uniqKey="Troum O" first="Orrin" last="Troum">Orrin Troum</name><affiliation wicri:level="1"><nlm:aff id="af10"><addr-line>Division of Rheumatology</addr-line>,<institution>University of Southern California Keck School of Medicine</institution>,<addr-line>Santa Monica, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bernasconi, Corrado" sort="Bernasconi, Corrado" uniqKey="Bernasconi C" first="Corrado" last="Bernasconi">Corrado Bernasconi</name><affiliation wicri:level="1"><nlm:aff id="af11"><institution>F. Hoffmann-La Roche Ltd</institution>,<addr-line>Basel</addr-line>,<country>Switzerland</country></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Huizinga, T W J" sort="Huizinga, T W J" uniqKey="Huizinga T" first="T W J" last="Huizinga">T W J. Huizinga</name><affiliation wicri:level="1"><nlm:aff id="af12"><addr-line>Department of Rheumatology</addr-line>,<institution>Leiden University Medical Center</institution>,<addr-line>Leiden</addr-line>,<country>Netherlands</country></nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24473673</idno><idno type="pmc">3995223</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995223</idno><idno type="RBID">PMC:3995223</idno><idno type="doi">10.1136/annrheumdis-2013-204761</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">002256</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002256</idno><idno type="wicri:Area/Pmc/Curation">002106</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002106</idno><idno type="wicri:Area/Pmc/Checkpoint">001704</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001704</idno><idno type="wicri:Area/Ncbi/Merge">001751</idno><idno type="wicri:Area/Ncbi/Curation">001751</idno><idno type="wicri:Area/Ncbi/Checkpoint">001751</idno><idno type="wicri:doubleKey">0003-4967:2014:Dougados M:clinical:radiographic:and</idno><idno type="wicri:Area/Main/Merge">003B73</idno><idno type="wicri:Area/Main/Curation">003B26</idno><idno type="wicri:Area/Main/Exploration">003B26</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study</title><author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name><affiliation wicri:level="1"><nlm:aff id="af1"><addr-line>Rheumatology B Department</addr-line>,<institution>Paris-Descartes University, Cochin Hospital</institution>,<addr-line>Paris</addr-line>,<country>France</country></nlm:aff><country xml:lang="fr">France</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kissel, Karsten" sort="Kissel, Karsten" uniqKey="Kissel K" first="Karsten" last="Kissel">Karsten Kissel</name><affiliation wicri:level="1"><nlm:aff id="af2"><institution>Roche Products Pty Ltd</institution>,<addr-line>Dee Why</addr-line>,<country>Australia</country></nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Conaghan, Philip G" sort="Conaghan, Philip G" uniqKey="Conaghan P" first="Philip G" last="Conaghan">Philip G. Conaghan</name><affiliation wicri:level="1"><nlm:aff id="af3"><institution>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit</institution>,<addr-line>Leeds</addr-line>,<country>UK</country></nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Mola, Emilio Martin" sort="Mola, Emilio Martin" uniqKey="Mola E" first="Emilio Martin" last="Mola">Emilio Martin Mola</name><affiliation wicri:level="1"><nlm:aff id="af4"><addr-line>Department of Rheumatology</addr-line>,<institution>Hospital Universitario La Paz</institution>,<addr-line>Madrid</addr-line>,<country>Spain</country></nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Schett, Georg" sort="Schett, Georg" uniqKey="Schett G" first="Georg" last="Schett">Georg Schett</name><affiliation wicri:level="1"><nlm:aff id="af5"><addr-line>Department of Internal Medicine and Institute for Clinical Immunology</addr-line>,<institution>University of Erlangen-Nuremberg</institution>,<addr-line>Erlangen</addr-line>,<country>Germany</country></nlm:aff><country xml:lang="fr">Allemagne</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Gerli, Roberto" sort="Gerli, Roberto" uniqKey="Gerli R" first="Roberto" last="Gerli">Roberto Gerli</name><affiliation wicri:level="1"><nlm:aff id="af6"><addr-line>Rheumatology Unit, Department of Medicine</addr-line>,<institution>University of Perugia</institution>,<addr-line>Perugia</addr-line>,<country>Italy</country></nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Hansen, Michael Sejer" sort="Hansen, Michael Sejer" uniqKey="Hansen M" first="Michael Sejer" last="Hansen">Michael Sejer Hansen</name><affiliation wicri:level="1"><nlm:aff id="af7"><addr-line>Department of Internal Medicine and Rheumatology</addr-line>,<institution>Copenhagen University Hospital</institution>,<addr-line>Gentofte</addr-line>,<country>Denmark</country></nlm:aff><country xml:lang="fr">Danemark</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Amital, Howard" sort="Amital, Howard" uniqKey="Amital H" first="Howard" last="Amital">Howard Amital</name><affiliation wicri:level="1"><nlm:aff id="af8"><addr-line>Department of Internal Medicine B and Research Center for Autoimmune Diseases</addr-line>,<institution>Sheba Medical Center</institution>,<addr-line>Tel-Hashomer</addr-line>,<country>Israel</country></nlm:aff><country xml:lang="fr">Israël</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Xavier, Ricardo M" sort="Xavier, Ricardo M" uniqKey="Xavier R" first="Ricardo M" last="Xavier">Ricardo M. Xavier</name><affiliation wicri:level="1"><nlm:aff id="af9"><addr-line>Division of Rheumatology</addr-line>,<institution>Hospital de Clínicas de Porto Alegre</institution>,<addr-line>Porto Alegre</addr-line>,<country>Brazil</country></nlm:aff><country xml:lang="fr">Brésil</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Troum, Orrin" sort="Troum, Orrin" uniqKey="Troum O" first="Orrin" last="Troum">Orrin Troum</name><affiliation wicri:level="1"><nlm:aff id="af10"><addr-line>Division of Rheumatology</addr-line>,<institution>University of Southern California Keck School of Medicine</institution>,<addr-line>Santa Monica, California</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Bernasconi, Corrado" sort="Bernasconi, Corrado" uniqKey="Bernasconi C" first="Corrado" last="Bernasconi">Corrado Bernasconi</name><affiliation wicri:level="1"><nlm:aff id="af11"><institution>F. Hoffmann-La Roche Ltd</institution>,<addr-line>Basel</addr-line>,<country>Switzerland</country></nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Huizinga, T W J" sort="Huizinga, T W J" uniqKey="Huizinga T" first="T W J" last="Huizinga">T W J. Huizinga</name><affiliation wicri:level="1"><nlm:aff id="af12"><addr-line>Department of Rheumatology</addr-line>,<institution>Leiden University Medical Center</institution>,<addr-line>Leiden</addr-line>,<country>Netherlands</country></nlm:aff><country xml:lang="fr">Pays-Bas</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of the Rheumatic Diseases</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>To assess the 1-year efficacy and safety of a regimen of tocilizumab plus methotrexate or placebo, which was augmented by a treat-to-target strategy from week 24.</p></sec><sec><title>Methods</title><p>ACT-RAY was a double-blind, 3-year trial. Adults with active rheumatoid arthritis despite methotrexate were randomised to add tocilizumab to ongoing methotrexate (add-on strategy) or to switch to tocilizumab plus placebo (switch strategy). Tocilizumab 8 mg/kg was administered every 4 weeks. Conventional open-label disease-modifying antirheumatic drugs (DMARDs) other than methotrexate were added at week 24 or later in patients with DAS28>3.2.</p></sec><sec><title>Results</title><p>556 patients were randomised; 85% completed 52 weeks. The proportion of patients receiving open-label DMARDs was comparable in the add-on (29%) and switch (33%) arms. Overall, week 24 results were maintained or further improved at week 52 in both arms. Some endpoints favoured the add-on strategy. Mean changes in Genant-modified Sharp scores were small; more add-on (92.8%) than switch patients (86.1%) had no radiographic progression. At week 52, comparable numbers of patients had antidrug antibodies (ADAs; 1.5% and 2.2% of add-on and switch patients, respectively) and neutralising ADAs (0.7% and 1.8%). Rates of serious adverse events and serious infections per 100 patient-year (PY) were 11.3 and 4.5 in add-on and 16.8 and 5.5 in switch patients. In patients with normal baseline values, alanine aminotransferase elevations >3× upper limit of normal were observed in 11% of add-on and 3% of switch patients.</p></sec><sec><title>Conclusions</title><p>Despite a trend favouring the add-on strategy, these data suggest that both tocilizumab add-on and switch strategies led to meaningful clinical and radiographic responses.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Grigor, C" uniqKey="Grigor C">C Grigor</name></author><author><name sortKey="Capell, H" uniqKey="Capell H">H Capell</name></author><author><name sortKey="Stirling, A" uniqKey="Stirling A">A Stirling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scott, Dl" uniqKey="Scott D">DL Scott</name></author><author><name sortKey="Wolfe, F" uniqKey="Wolfe F">F Wolfe</name></author><author><name sortKey="Huizinga, Tw" uniqKey="Huizinga T">TW Huizinga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Listing, J" uniqKey="Listing J">J Listing</name></author><author><name sortKey="Strangfeld, A" uniqKey="Strangfeld A">A Strangfeld</name></author><author><name sortKey="Rau, R" uniqKey="Rau R">R Rau</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soliman, Mm" uniqKey="Soliman M">MM Soliman</name></author><author><name sortKey="Ashcroft, Dm" uniqKey="Ashcroft D">DM Ashcroft</name></author><author><name sortKey="Watson, Kd" uniqKey="Watson K">KD Watson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zink, A" uniqKey="Zink A">A Zink</name></author><author><name sortKey="Listing, J" uniqKey="Listing J">J Listing</name></author><author><name sortKey="Kary, S" uniqKey="Kary S">S Kary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Furst, De" uniqKey="Furst D">DE Furst</name></author><author><name sortKey="Koehnke, R" uniqKey="Koehnke R">R Koehnke</name></author><author><name sortKey="Burmeister, Lf" uniqKey="Burmeister L">LF Burmeister</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schnabel, A" uniqKey="Schnabel A">A Schnabel</name></author><author><name sortKey="Reinhold Keller, E" uniqKey="Reinhold Keller E">E Reinhold-Keller</name></author><author><name sortKey="Willmann, V" uniqKey="Willmann V">V Willmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Verstappen, Sm" uniqKey="Verstappen S">SM Verstappen</name></author><author><name sortKey="Jacobs, Jw" uniqKey="Jacobs J">JW Jacobs</name></author><author><name sortKey="Van Der Veen, Mj" uniqKey="Van Der Veen M">MJ van der Veen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sebba, A" uniqKey="Sebba A">A Sebba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jones, G" uniqKey="Jones G">G Jones</name></author><author><name sortKey="Sebba, A" uniqKey="Sebba A">A Sebba</name></author><author><name sortKey="Gu, J" uniqKey="Gu J">J Gu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Beaulieu, A" uniqKey="Beaulieu A">A Beaulieu</name></author><author><name sortKey="Rubbert Roth, A" uniqKey="Rubbert Roth A">A Rubbert-Roth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Genovese, Mc" uniqKey="Genovese M">MC Genovese</name></author><author><name sortKey="Mckay, Jd" uniqKey="Mckay J">JD McKay</name></author><author><name sortKey="Nasonov, El" uniqKey="Nasonov E">EL Nasonov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Emery, P" uniqKey="Emery P">P Emery</name></author><author><name sortKey="Keystone, E" uniqKey="Keystone E">E Keystone</name></author><author><name sortKey="Tony, Hp" uniqKey="Tony H">HP Tony</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kremer, J" uniqKey="Kremer J">J Kremer</name></author><author><name sortKey="Furst, D" uniqKey="Furst D">D Furst</name></author><author><name sortKey="Burgos Vargas, R" uniqKey="Burgos Vargas R">R Burgos-Vargas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khraishi, M" uniqKey="Khraishi M">M Khraishi</name></author><author><name sortKey="Alten, R" uniqKey="Alten R">R Alten</name></author><author><name sortKey="Gomez Reino, Jj" uniqKey="Gomez Reino J">JJ Gomez-Reino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dougados, M" uniqKey="Dougados M">M Dougados</name></author><author><name sortKey="Kissel, K" uniqKey="Kissel K">K Kissel</name></author><author><name sortKey="Sheeran, T" uniqKey="Sheeran T">T Sheeran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bruynesteyn, K" uniqKey="Bruynesteyn K">K Bruynesteyn</name></author><author><name sortKey="Boers, M" uniqKey="Boers M">M Boers</name></author><author><name sortKey="Kostense, P" uniqKey="Kostense P">P Kostense</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aletaha, D" uniqKey="Aletaha D">D Aletaha</name></author><author><name sortKey="Strand, V" uniqKey="Strand V">V Strand</name></author><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Klarenbeek, Nb" uniqKey="Klarenbeek N">NB Klarenbeek</name></author><author><name sortKey="Koevoets, R" uniqKey="Koevoets R">R Koevoets</name></author><author><name sortKey="Van Der Heijde, Dm" uniqKey="Van Der Heijde D">DM van der Heijde</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van De Putte, Lb" uniqKey="Van De Putte L">LB van de Putte</name></author><author><name sortKey="Atkins, C" uniqKey="Atkins C">C Atkins</name></author><author><name sortKey="Malaise, M" uniqKey="Malaise M">M Malaise</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dore, Rk" uniqKey="Dore R">RK Dore</name></author><author><name sortKey="Mathews, S" uniqKey="Mathews S">S Mathews</name></author><author><name sortKey="Schechtman, J" uniqKey="Schechtman J">J Schechtman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pascual Salcedo, D" uniqKey="Pascual Salcedo D">D Pascual-Salcedo</name></author><author><name sortKey="Plasencia, C" uniqKey="Plasencia C">C Plasencia</name></author><author><name sortKey="Ramiro, S" uniqKey="Ramiro S">S Ramiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stubenrauch, K" uniqKey="Stubenrauch K">K Stubenrauch</name></author><author><name sortKey="Wessels, U" uniqKey="Wessels U">U Wessels</name></author><author><name sortKey="Birnboeck, H" uniqKey="Birnboeck H">H Birnboeck</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weinblatt, Me" uniqKey="Weinblatt M">ME Weinblatt</name></author><author><name sortKey="Kremer, J" uniqKey="Kremer J">J Kremer</name></author><author><name sortKey="Cush, J" uniqKey="Cush J">J Cush</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bykerk, Vp" uniqKey="Bykerk V">VP Bykerk</name></author><author><name sortKey="Ostor, Aj" uniqKey="Ostor A">AJ Ostor</name></author><author><name sortKey="Alvaro Gracia, J" uniqKey="Alvaro Gracia J">J Alvaro-Gracia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smolen, Js" uniqKey="Smolen J">JS Smolen</name></author><author><name sortKey="Landewe, R" uniqKey="Landewe R">R Landewe</name></author><author><name sortKey="Breedveld, Fc" uniqKey="Breedveld F">FC Breedveld</name></author></analytic></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Brésil</li><li>Danemark</li><li>Espagne</li><li>France</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>États-Unis</li></country></list><tree><country name="France"><noRegion><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Kissel, Karsten" sort="Kissel, Karsten" uniqKey="Kissel K" first="Karsten" last="Kissel">Karsten Kissel</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Conaghan, Philip G" sort="Conaghan, Philip G" uniqKey="Conaghan P" first="Philip G" last="Conaghan">Philip G. Conaghan</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Mola, Emilio Martin" sort="Mola, Emilio Martin" uniqKey="Mola E" first="Emilio Martin" last="Mola">Emilio Martin Mola</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Schett, Georg" sort="Schett, Georg" uniqKey="Schett G" first="Georg" last="Schett">Georg Schett</name></noRegion></country><country name="Italie"><noRegion><name sortKey="Gerli, Roberto" sort="Gerli, Roberto" uniqKey="Gerli R" first="Roberto" last="Gerli">Roberto Gerli</name></noRegion></country><country name="Danemark"><noRegion><name sortKey="Hansen, Michael Sejer" sort="Hansen, Michael Sejer" uniqKey="Hansen M" first="Michael Sejer" last="Hansen">Michael Sejer Hansen</name></noRegion></country><country name="Israël"><noRegion><name sortKey="Amital, Howard" sort="Amital, Howard" uniqKey="Amital H" first="Howard" last="Amital">Howard Amital</name></noRegion></country><country name="Brésil"><noRegion><name sortKey="Xavier, Ricardo M" sort="Xavier, Ricardo M" uniqKey="Xavier R" first="Ricardo M" last="Xavier">Ricardo M. Xavier</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Troum, Orrin" sort="Troum, Orrin" uniqKey="Troum O" first="Orrin" last="Troum">Orrin Troum</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Bernasconi, Corrado" sort="Bernasconi, Corrado" uniqKey="Bernasconi C" first="Corrado" last="Bernasconi">Corrado Bernasconi</name></noRegion></country><country name="Pays-Bas"><noRegion><name sortKey="Huizinga, T W J" sort="Huizinga, T W J" uniqKey="Huizinga T" first="T W J" last="Huizinga">T W J. Huizinga</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:3995223
|texte= Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24473673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |